Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
Jazyk: angličtina
Zdroj: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1130.
DOI: 10.1038/s43018-024-00797-y
Databáze: MEDLINE